Attached files
| file | filename |
|---|---|
| 8-K - 8-K - BIO-PATH HOLDINGS INC | v461863_8k.htm |
| EX-99.1 - EXHIBIT 99.1 - BIO-PATH HOLDINGS INC | v461863_ex99-1.htm |
Exhibit 99.2
Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference
HOUSTON—March 14, 2017 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer of Bio-Path Holdings, will present a corporate overview at the upcoming Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 1:00 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed under “Presentations and Publications” in the Media section of the Company’s website at www.biopathholdings.com or at https://www.veracast.com/webcasts/opco/healthcare2017/33108275511.cfm.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
# # #
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations